Sex: F
Vaccine: RAB, UNK, UNK
Symptoms: Interchange of vaccine products
Clinical narrative: The patient first got five dozes of Imovax, then two more dozes of RabAvert.; The patient had itching with the first shot of RabAvert.; Case reference number US-BN-2023-010735 is a spontaneous case initially received from a consumer (reference number: USBAV23-2171) on 26-Dec-2023 and concerns a female patient of unspecified age.  The patient's medical history and concomitant medication details were not provided.  On 10-Nov-2023, the patient was attacked by an armadillo, and was advised to receive rabies vaccination.  On unknown dates, unknown amount of time after the contact, the patient was vaccinated with five doses of co-suspect Imovax, also reported as Ivamax, (batch number unknown), via unknown route, four doses were given in the hip, and the fifth was given in the arm, as reported, for post-exposure immunization.  On unspecified date, unknown amount of time after the contact, the patient received co-suspect immunoglobulins (brand name unknown, batch number: unknown),at an unknown dose, route or site of administration, for post-exposure immunization.  On unspecified date, the patient got antibody titer test, and results were undetectable, less than 0.1 (unit not provided), as reported.  On unspecified date, reported as after vaccination of five doses of Imovax and a dose of immunoglobulins, the patient was vaccinated with the first dose of RabAvert, reported as booster, (batch number: unknown), at unknown dose, route or site of administration, for postexposure treatment of rabies (explicitly coded as 'interchange of vaccine products').  On unspecified date, unknown amount of time after the first dose, the patient had itching and was treated with steroids (brand name: unknown), instead of Benadryl (cetirizine dihydrochloride) as reported.  On unspecified date, unknown time after the first dose of RabAvert, the patient was vaccinated with the second dose (batch number: unknown), at unknown dose, route or site of administration.  At the time of the initial report, the outcome for the event of itching was unknown.  The reporter assessed the event of itching as non-serious and as possibly related to RabAvert vaccination.  No further information was provided.; Reporter's Comments: A female patient of unspecified age was vaccinated with the first dose of RabAvert after receiving five doses of Imovax for postexposure treatment of rabies, which is considered as interchange of vaccine products. On unspecified date, unknown amount of time after the first dose, the patient experienced pruritus. Pruritus is unlisted for RabAvert as per summary and expected per insert, whilst interchange of vaccine products is listed per company convention. The patient's medical history and concomitant medication details were not provided. Due to implied temporal relationship and lack of alternative etiology, the causality for reported pruritus is assessed as related to RabAvert. Interchange of vaccine products is not related to RabAvert, but to a human factor. The case is non-serious.; Sender's Comments: A female patient of unspecified age was vaccinated with the first dose of RabAvert after receiving five doses of Imovax for postexposure treatment of rabies, which is considered as interchange of vaccine products. On unspecified date, unknown amount of time after the first dose, the patient experienced pruritus. Pruritus is unlisted for RabAvert as per summary and expected per insert, whilst interchange of vaccine products is listed per company convention. The patient's medical history and concomitant medication details were not provided. Due to implied temporal relationship and lack of alternative etiology, the causality for reported pruritus is assessed as related to RabAvert. Interchange of vaccine products is not related to RabAvert, but to a human factor. The case is non-serious.